Litcius/Paper detail

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont

2021Nature Medicine527 citationsDOIOpen Access PDF

Topics & Concepts

Cytokine release syndromeMedicineClinical endpointInternal medicineFollicular lymphomaInterim analysisOncologyInterquartile rangeClinical trialImmunologyLymphomaImmunotherapyChimeric antigen receptorCancerCAR-T cell therapy researchLymphoma Diagnosis and TreatmentIntegrated Circuits and Semiconductor Failure Analysis
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial | Litcius